TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06007690
Drug: Bel-sar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bel-sar via suprachoroidal administration followed by laser application.
Study: NCT05182905
Drug: AZD1390
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 0: AZD1390 administered orally daily for 3 days prior to resection~Phase 1b: AZD1390 administered daily for 5 days concurrently with standard of care radiation therapy
Study: NCT06298461
Drug: KleanLyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative for colonoscopy bowel preparation
Study: NCT05118204
Drug: BUP microdose induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be started on a 5-day BUP microdose induction protocol (without stopping full agonists).~Day 1: participants will receive buprenorphine (Belbuca) 225 mcg mg every 12 hours Day 2: participants will receive buprenorphine (Belbuca) 450 mcg every 8 hours Day 3: participants will receive buprenorphine-naloxone 2-0.5 mg every 8 hours Day 4: participants will receive buprenorphine-naloxone 4-1 mg every 8 hours Day 5: participants will receive buprenorphine-naloxone 8-2 mg every 12 hours
Study: NCT06717126
Drug: Investigator choice of standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator will choose the most appropriate treatment standardly given to patients
Study: NCT06368986
Drug: VH4011499 Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH4011499 administered in fasted or fed conditions.
Study: NCT06368986
Drug: VH4011499 Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH4011499 Dose B administered in fasted or fed conditions.
Study: NCT05797233
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m\^2 IV infusion over 30 minutes on days -5, -4 and -3
Study: NCT04532502
Drug: Anesthetics, Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work environmental exposure
Study: NCT05433584
Drug: Antihyperglycemic medication
Normalized name: ANTIHYPOGLYCEMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT06175065
Drug: RLS-0071
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLS-0071, will be administered as an IV infusion 10 mg/kg. Planned infusion duration is 8 minutes.
Study: NCT06175065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (commercial sterile saline), will be administered as an IV infusion. Planned infusion duration is 8 minutes.
Study: NCT05902598
Drug: VSA001 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: also referred to as ARO-APOC3
Study: NCT05902598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching VSA001 injection
Study: NCT04828161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV on day 1 only.
Study: NCT06065657
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
Study: NCT05583721
Drug: [13N]NH3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ammonia N 13 (a radioactive tracer) will be given per intravenous (IV) injection for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.
Study: NCT05950802
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Higher dose than traditional conditioning chemo
Study: NCT05814159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sub cutaneous daily injection
Study: NCT06305780
Drug: IVIG + Coordinated Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IVIG for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator.
Study: NCT06305780
Drug: IVIG Placebo + Coordinated Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo administration.~Participants will receive IVIG placebo for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator.
Study: NCT06305780
Drug: IVIG + Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IVIG for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG administration.
Study: NCT06305780
Drug: IVIG Placebo + Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline given intravenously will be the control (placebo) product. The normal saline will be of similar formulation and appearance to IVIG.~Participants will receive IVIG placebo for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG placebo administration.
Study: NCT04956666
Drug: Lyophilized S95014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient was administrated, over 1 to 2 hours, every 2 weeks Lyophilized S95014 intravenously at the dose of 1000, 2000 or 2500U/m2, as per investigator's judgement.~In total, 9 infusions of lyophilized S95014 were administrated (at week 7, 9, 11, 15, 17, 19, 23, 25 and 27).Patients received other backbone chemotherapy agents as per ALL-MB 2015.
Study: NCT05382338
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06130826
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive M5A-IL2 ICK SC
Study: NCT05751044
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous
Study: NCT05983588
Drug: RAVICTI 1.1 g/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)
Study: NCT05983588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)
Study: NCT05342792
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine : 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
Study: NCT06521866
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy：Oxaliplatin: 85 mg/m² IV on Day 1 Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours~Maintenance therapy:~Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours
Study: NCT06521866
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab: 400 mg/m² IV on Day 1, then 250 mg/m² IV weekly ; Bevacizumab: 5 mg/kg IV on Day 1
Study: NCT06557772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Injection solution Route of administration: SC injection
Study: NCT05020860
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 IV administered on Day 1 of each 14-day cycle
Study: NCT05020860
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV administered on Day 1 of each 14-day cycle
Study: NCT06362746
Drug: Non-immunogenic recombinant staphylokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
Study: NCT06362746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of placebo reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
Study: NCT06162390
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following a sequential allocation scheme, the predetermined Ce of remifentanil for each patient will be determined by the Dixon up-and-down method. The Ce of remifentanil for the first patient will be 4.0 ng/ml, and then the remifentanil Ce will be increased or decreased in 0.5 ng/ml increments for subsequent patients depending on the success or failure of intubation.~The Ce of remifentanil to provide acceptable intubation at low dose neuromuscular blockade, the primary outcome, will be determined by obtaining seven crossovers of patients with acceptable intubation/unacceptable intubation and then calculating the mean of the midpoint doses for each independent pair of patients. According to previous studies that estimated EC50 by Dixon's up-and-down method, 6-8 failure/success crossover pairs are required, so this study aims to collect independent data of 7 pairs of intubation acceptable/unacceptable patients.
Study: NCT05764876
Drug: Azithromycin Oral Tablet
Normalized name: azithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet of azithromycin 30mg/kg maximum 2gr single dose.
Study: NCT04942626
Drug: Kineret 100 MG in 0.67 ML Prefilled Syringe
Normalized name: Kineret 100 MG in 0.67 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg s.c. (Kineret) will be administered from day -10 (i.e. 10 days before initiation of RT) to the last day of RT.
Study: NCT04942626
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered using a 3+3 dose escalation design (500 mg/m2 bid, 650 mg/m2 bid and 825 mg/m2 bid po, respectively) from day 1 to day 40 of RT including weekends.
Study: NCT06247735
Drug: K-808 (Dose A)
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT06247735
Drug: K-808 (Dose B)
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT06247735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT04451863
Drug: Low Myrcene
Normalized name: myrcene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporized Myrcene (0.5 mg)
Study: NCT04451863
Drug: High Myrcene
Normalized name: myrcene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporized Myrcene (12.0 mg)
Study: NCT04451863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporized Placebo
Study: NCT05268120
Drug: doxycycline 200 mg q.d. - rifampicin 600mg b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both first choice treatments in Dutch guideline for MRSA decolonization
Study: NCT05464810
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05753215
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to randomization, SOC antibacterial therapy will be selected by the subject's treating physician.
Study: NCT04782830
Drug: placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill will be taken for 7 days at the same frequency as their regular treatment with either midodrine or atomoxetine.
Study: NCT06288477
Drug: Neo-Putty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).
Study: NCT05739383
Drug: Placebo in 1.5ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo in 1.5ml solution for injection
Study: NCT06095258
Drug: Traditional Chinese medicine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: About four to six Chinese medicine practitioners with five to twenty years of clinical work experience will be responsible for patient diagnosis and prescription treatment, and use a uniformly designed data collection form to record the patient's medical history, clinical symptoms and signs, tongue and pulse conditions, and other information. Patients in the treatment group will receive individualized Chinese medicine treatment prescriptions. Patients in the control group received conventional Western medicine treatment, and about 3 to four Western medicine practitioners with five to twenty years of work experience will be responsible for the conventional medicine prescription. The treatment of the two groups will last for four weeks, and the patients will be followed up for four weeks after the treatment. A patient diary will be provided to all participants for recording the drug compliance and any adverse event during the treatment period.
Study: NCT05655312
Drug: [203Pb]VMT01
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[203Pb\]VMT01 is administered intravenous (IV) as an imaging agent for SPECT/CT
Study: NCT04799327
Drug: SHR20004
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR20004：low dose
Study: NCT04799327
Drug: SHR20004
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR20004: medium dose
Study: NCT04799327
Drug: SHR20004
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR20004: high dose
Study: NCT04799327
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05655312
Drug: [212Pb]VMT01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with positive uptake of \[203Pb\]VMT01 will receive a fixed dose of \[212Pb\]VMT01 administered IV every 8 weeks starting at Cycle 1 Day 1.
Study: NCT06095258
Drug: Western medicine treatment
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine doctors will mainly use symptomatic drugs to treat long COVID. For example, cough medicine (such as codeine), bronchodilators (such as ventolin), expectorants (such as fluimucil) and so on are used to treat cough, shortness of breath, or other respiratory symptoms. Non-steroidal anti-inflammatory painkillers (such as panadol) are often used for treating headaches, and sedative-hypnotic drugs (such as stilnox) are often used to treat insomnia.
Study: NCT05170464
Drug: Caffeine Powder
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive powdered caffeine dissolved in one cup of water (1.2mg/kg)
Study: NCT05488171
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of placebo.
Study: NCT05361161
Drug: Transarterial Chemoembolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arterial infusion chemotherapy (THP + oxaliplatin + raltitrexed) and THP combined with lipiodol embolization for 2 times, with an interval of 1 month.
Study: NCT06013423
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Receive IV
Study: NCT04977986
Drug: ZYN002 - transdermal gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutically manufactured cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery)
Study: NCT04977986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo formulated as a clear gel that can be applied to the skin (transdermal delivery)~Other Names:~Placebo Comparator Matching Placebo
Study: NCT00429923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06568861
Drug: ALG-097558
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of ALG-097558 200 mg (2 x 100 mg tablets)
Study: NCT05769309
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl boluses of 0.5-to-1 µg/kg titrated according to haemodynamic parameters.
Study: NCT06068023
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients meeting the criteria of post-operative adenocarcinoma of the ampulla of Vater will be enrolled, with adjuvant chemotherapy commencing within 8 weeks of recovery from surgery. Those undergoing palliative intent surgery or palliative chemotherapy are ineligible for the ADAPTA study.~The ADAPTA study's adjuvant chemotherapy involves 8-12 FOLFIRINOX cycles (Arm 2) repeated 2 weeks. Given patient outcomes, 8 cycles of FOLFIRINOX are deemed sufficient due to completion challenges in prior research. FOLFIRINOX regimen mirrors the modified version from the ACCORD/PRODIGE trial for metastatic pancreatic cancer. This trial adapts mFOLFIRINOX for standard practice.
Study: NCT06068023
Drug: Capox
Approvals — FDA: no, EMA: no, PMDA: no
Description: or 8 CAPOX cycles (Arm 1) every 3 weeks.
Study: NCT05053893
Drug: EPO; ACEI / ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Select the appropriate ACEI /ARB according to the subject's situation or follow its previous medication
Study: NCT04986423
Drug: ZEN003694
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72 mg PO QD
Study: NCT05681299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be taken by nightly subcutaneous injection at 9-11 pm.
Study: NCT05081765
Drug: Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: correlation between C through and taken drug
Study: NCT06273462
Drug: Palmitoylethanolamide 600mg twice a day
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg palmitoylethanolamide twice a day
Study: NCT05600660
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
Study: NCT06557018
Drug: traditional peri-articular injection
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: traditional peri-articular injection group
Study: NCT06075667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06382831
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Control given Opioid balanced anesthesia
Study: NCT06079775
Drug: Xeruborbactam Oral Prodrug Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT05089279
Drug: D113
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05882045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06538116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04895748
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: mTOR inhibitor
Study: NCT05639751
Drug: PRT3789
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT3789 will be administered by intravenous infusion
Study: NCT06301802
Drug: Anticholinergic
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: antimuscarinic once daily
Study: NCT05664880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsule to 2 MCG Paricalcitol Oral Capsule
Study: NCT06345066
Drug: LY3841136
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT06345066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT06079398
Drug: Navepegritide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly subcutaneous injection of 100 µg/kg Navepegritide
Study: NCT06079398
Drug: Placebo for Navepegritide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide
Study: NCT05516498
Drug: Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)
Study: NCT05855746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant receive, in addition to standard of care therapy, six months of placebo (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization.~The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF \< 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision.
Study: NCT05128903
Drug: [18F]DPA714
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection~* Before or within 2 weeks of starting radiation therapy~* Before starting chemotherapy~* 1 year after the start of radiation therapy Timing cont.~* 1.5 to 2 years after the start of radiation therapy
Study: NCT06166472
Drug: AK132
Normalized name: Aklomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion, specified dose on specified days.
Study: NCT04970446
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive a one week course of antibiotic therapy.
Study: NCT04892940
Drug: Analgesic protocol
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized in the control group receive the usual analgesic protocol of the department postoperatively.